Agilent Technologies, Inc. (A) company profile
Close on Nov 12, 2026Market cap $48.78BP/E 34.1Yield 0.57%
About Agilent Technologies
Laboratory Analytical Instruments, SIC 3826
Agilent Technologies, Inc. provides application-focused solutions encompassing instruments, software, consumables, and services across laboratory workflows. The company organizes its operations into three primary segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. Key products include chromatography and mass spectrometry systems, cancer pathology platforms, cell analysis tools, genomic reagents, automation systems, and lab management software. It also offers contract development and manufacturing for oligonucleotide therapeutics, alongside instrument maintenance and analytical supplies. Customers encompass pharmaceutical and biopharmaceutical companies, clinical diagnostics laboratories, academic and government research organizations, and industrial testing facilities in food, chemical, environmental, and forensic sectors.
The enterprise maintains an international presence, employing approximately 18,100 people worldwide across its business units. Its primary manufacturing, research, and development activities are located in multiple United States facilities as well as sites in Australia, Canada, China, Denmark, Germany, Italy, Japan, Malaysia, the Netherlands, Singapore, and the United Kingdom. In addition, its direct service network operates across 28 countries. Incorporated in Delaware, the organization coordinates centralized fulfillment, supply chain, and global support infrastructure to serve its diverse customer accounts.
Summary of the business section of Agilent Technologies's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Agilent Technologies, Inc.
- Founded
- 1999
- Headquarters
- Santa Clara, CA
- Address
- 5301 Stevens Creek Blvd 95051
- Phone
- (408) 345-8886
- Website
- www.agilent.com
- Employees
- 18,100, Oct 31, 2025
- Industry
- Laboratory Analytical Instruments
- Incorporated in
- Delaware
- Fiscal year ends
- October 31
- Auditor
- PricewaterhouseCoopers LLP, San Jose, California
Stock & identifiers
- Ticker
- A
- Exchange
- NYSE
- IPO date
- Nov 18, 1999
- Shares outstanding
- 282M, Aug 26, 2026
- Public float
- $26.60B, Apr 30, 2025
- Filer category
- Large accelerated filer
- SEC CIK
- 1090872
- CUSIP
- 00846U101
- ISIN
- US00846U1016
- FIGI
- BBG000C2V3D6
- Share class FIGI
- BBG001SCTQY4
- LEI
- QUIX8Y7A2WP0XRMW7G29
- EIN
- 77-0518772
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Padraig McDonnell | President and CEO, Director | 65,842 |
| Jonah Prevost Kirkwood | Senior Vice President | 14,108 |
| Timothy Charles Downs | VP, Chief Accounting Officer | 8,872 |
| Michael Steven Buckner | Senior Vice President | 8,887 |
| Simon May | Senior Vice President | 14,015 |
| Meghan Henson | Senior Vice President | 6,890 |
| Angelica Riemann | Senior Vice President | 29,146 |
| Rodney Gonsalves | V.P., Corporate Controller | 32,394 |
| Bret DiMarco | Senior Vice President | 12,203 |
| Jianmiao Mike Zhang | Senior Vice President | 11,639 |
| Adam Stewart Elinoff | Senior Vice President and CFO | 11,726 |
| Henrik Ancher-Jensen | Sr Vice President | 86,426 |
| Robert W. McMahon | Sr. VP and CFO | 168,754 |
| Philip Binns | Senior Vice President | 10,650 |
| Glenn S. Boehnlein | Director | 35 |
| Mikael Dolsten | Director | 4,924 |
| Daniel K. Podolsky | Director | 38,180 |
| Sue H. Rataj | Director | 23,617 |
| Mala Anand | Director | 16,705 |
| Boon Hwee Koh | Director | 63,184 |
| Pascal Soriot | Director | 3,331 |
| George A. Scangos | Director | 40,693 |
| Judy L. Brown | Director | 3,835 |
| Dow R. Wilson | Director | 20,369 |
| Otis W. Brawley | Director | 13,874 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 | $12.83M | $14.64M | $3.80M | $148 | $194 |
| FY2024 Mr Mcdonnell | $9.04M | $8.92M | $5.92M | $131 | $174 |
| FY2024 Mr Mcmullen | $16.62M | $21.20M | $5.92M | $131 | $174 |
| FY2023 | $16.02M | $1.01M | $3.68M | $103 | $134 |
| FY2022 | $16.65M | $10.46M | $4.17M | $137 | $130 |
| FY2021 | $15.97M | $31.77M | $3.76M | $155 | $140 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Stock awards | Option awards | Incentive pay | Other | Total | vs. prior year |
|---|---|---|---|---|---|---|---|---|
| Padraig McDonnell President; Chief Executive Officer | $1.14M | – | $8.17M | $2.02M | $1.44M | $61.47K | $12.83M | +42% |
| Rodney Gonsalves Vice President; Controller; Principal Accounting Officer; Interim Chief Financial Officer | $513.56K | – | $1.69M | $175.92K | $291.64K | $26.88K | $2.70M | – |
| Simon May Senior Vice President, Agilent President Life Sciences and Diagnostics Market Group | $635.39K | $500.00K | $1.80M | $444.96K | $472.40K | $17.41K | $3.87M | +4% |
| Angelica Riemann Senior Vice President, Agilent President Agilent Cross-Lab Group | $591.35K | – | $1.68M | $413.89K | $520.45K | $12.96K | $3.21M | – |
| Bret DiMarco Senior Vice President, Chief Legal Officer | $679.81K | – | $1.99M | $491.52K | $475.47K | $21.57K | $3.66M | – |
| Robert McMahon Former Senior Vice President; Former Chief Financial Officer | $665.00K | – | $4.00M | $827.78K | – | $44.58K | $5.54M | -38% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
Employees
Headcount reported in annual reports
“As of October 31, 2025, we employed approximately 18,100 people worldwide.”
Corporate history
Events identified from SEC filings
See a number that looks wrong?